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However, these drugs act on central nervous system (CNS) muscarinic receptors and this action affect cognitive function. This study evaluated the cognitive effect of antimuscarinic using meta-analysis.
METHODS: A systematic literature review located randomized controlled trials of antimuscarinic and cognitive function in adults. We searched MEDLINE, EMBASE, and the Cochrane. Meta-analysis was based on Cochrane Review Methods. We searched the randomized controlled trials using MESH term including all antimuscarinic agents (Darifenacin, Fesoterodine, Oxybutinin, Propiverine, Solifenacin, Tolterodine, Trospium). We performed all statistical analyses with RevMan version 5.3.
RESULTS: Initial searches of the databases identified 137 publications (Darifenacin (n[14) , Fesoterodine (n[7) , Oxybutinin (n[44) , Propiverine (n[8) , Solifenacin(n[19) , Tolterodine (n[28) , Trospium (n[17) ). In addition to removing 73 duplicate articles, 12 publications were eliminated as their titles and abstracts showed that they did not fulfill the selection criteria. For the remaining 15 publications, we obtained full manuscripts for scrutiny, subsequently identifying eight publications with potentially relevant studies. Three studies which included the reaction time as cognitive function marker were finally included. Three studies (686 participants) were included. Antimuscarinics administration demonstrated no significant effect of the cognitive function (P [ 0.73, I2 [ 0%)
CONCLUSIONS: Although each antimuscarinic agents were different, antimuscarinics administration has not affected the cognitive function using reaction time.
However, we observed the effect of antimuscarinics administration on the cognitive function using MMSE.
Source of Funding: none

PD37-02 HIGHER SALT INTAKE AND NON-DIPPING BLOOD PRESSURE ARE ASSOCIATED WITH NOCTURNAL POLYURIA IN PATIENTS WITH LOWER URINARY TRACT SYMPTOMS
Misato Takayama*, So Omori, Daiki Ikarashi, Renpei Kato, Yoichiro Kato, Mitsugu Kanehira, Ryo Takata, Wataru Obara, Iwate, Japan INTRODUCTION AND OBJECTIVES: 1)Nocturnal polyuria (NP) is the largest factor of nocturia. We have reported the relation between NP and non-dipping blood pressure (BP) in male LUTS patients (Takayama M, et al: Low Urin Tract Symptoms.2018; 29) . The aims of the present study is to examine the factors for NP in LUTS patients (including female patients). We especially focused on salt intake, non-dipping BP and resistant hypertension(Resistant hypertension is defined as uncontrolled BP after treatment with three or more antihypertensives and diuretics).
METHODS: 1) The subject of this study was 323 patients with LUTS who were treated (256 men and 67 women). Their urinary condition was evaluated using frequency volume charts. Patients were divided into two groups (the NP group and the non-NP group) based on nocturnal polyuria index (NPi 0.33). We also investigated their characteristics, medical history and medications. 2) 34 patients (17 NP patients and 17 non-NP patients) were monitored for 24-h using portable automatic blood pressure monitors. We calculated the rate of nocturnal BP fall. Dipping, which is normal type of nocturnal BP, was defined as a nocturnal BP fall of more than 10%. Non-dipping was defined as a nocturnal BP fall of less than 10% or rise from daytime BP.We also corrected their spot urine samples to evaluate estimated Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e661
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